Literature DB >> 19187456

A multi-drug intoxication fatality involving Xyrem (GHB).

Brianne E Akins1, Estuardo Miranda, J Matthew Lacy, Barry K Logan.   

Abstract

Gamma-hydroxybutyrate (GHB) is best known as a recreational depressant drug, whose use has also been implicated in drug facilitated sexual assault cases. It is also available as a therapeutic agent (Xyrem) used for the treatment of daytime sleepiness or cataplexy associated with narcolepsy. This is a report of a case of a 53-year-old woman undergoing treatment with Xyrem for narcolepsy. The decedent was also prescribed tramadol, gabapentin, cetirizine, modafinil, carisoprodol, and Xyrem. Toxicological analysis of the blood revealed GHB 165.6 mg/L, and 90.7 mg/L in the urine. Blood GHB concentrations in the range 156-260 mg/L have been reported to induce moderately sound sleep. The combined use of central nervous system depressant drugs, together with her problematic sleep apnea, and snoring (both contraindications for GHB use) were determined to have caused this subject's death. The manner of death was determined to be accidental.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187456     DOI: 10.1111/j.1556-4029.2008.00965.x

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  5 in total

Review 1.  Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion.

Authors:  Y Grace Wang; Todd J Swick; Lawrence P Carter; Michael J Thorpy; Neal L Benowitz
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

2.  Catathrenia under sodium oxybate in narcolepsy with cataplexy.

Authors:  Francesca Poli; Lara Ricotta; Stefano Vandi; Christian Franceschini; Fabio Pizza; Vincenzo Palaia; Keivan Kaveh Moghadam; Donatella Banal; Roberto Vetrugno; Michael J Thorpy; Giuseppe Plazzi
Journal:  Sleep Breath       Date:  2011-04-12       Impact factor: 2.816

3.  Further research on Xyrem®/sodium oxybate treatment of patients with obstructive sleep apnea is needed.

Authors:  Deborah L Zvosec; Stephen W Smith; Mark W Mahowald
Journal:  Sleep Breath       Date:  2010-09-18       Impact factor: 2.816

4.  Abuse Potential of Soma: the GABA(A) Receptor as a Target.

Authors:  Lorie A Gonzalez; Michael B Gatch; Michael J Forster; Glenn H Dillon
Journal:  Mol Cell Pharmacol       Date:  2009-01-01

Review 5.  Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing.

Authors:  Neil T Feldman
Journal:  Sleep Breath       Date:  2009-07-23       Impact factor: 2.816

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.